New approaches in the treatment of hypertension

Circulation Research
S Oparil, Roland E Schmieder

Abstract

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. Despite a plethora of available treatment options, a substantial portion of the hypertensive population has uncontrolled blood pressure. The unmet need of controlling blood pressure in this population may be addressed, in part, by developing new drugs and devices/procedures to treat hypertension and its comorbidities. In this Compendium Review, we discuss new drugs and interventional treatments that are undergoing preclinical or clinical testing for hypertension treatment. New drug classes, eg, inhibitors of vasopeptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/III of development, while inhibitors of aminopeptidase A, dopamine β-hydroxylase, and the intestinal Na(+)/H(+) exchanger 3, agonists of components of the angiotensin-converting enzyme 2/angiotensin(1-7)/Mas receptor axis and vaccines directed toward angiotensin II and its type 1 receptor are in...Continue Reading

References

Jul 1, 1975·Endocrinology·P CorvolJ Mahoudeau
Jul 1, 1991·Physiological Reviews·A Stella, A Zanchetti
Jan 1, 1991·Neurologia Medico-chirurgica·I YamamotoO Sato
Feb 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T KawamotoH Imura
Mar 1, 1989·American Heart Journal·J B MichelJ Ménard
Feb 25, 1988·The New England Journal of Medicine·R C Goodlin
Aug 29, 1974·The New England Journal of Medicine·S Oparil, E Haber
Dec 1, 1984·The Journal of Clinical Endocrinology and Metabolism·S W Graves, G H Williams
Sep 1, 1984·American Journal of Obstetrics and Gynecology·J P GusdonJ F Hennessy
Jan 1, 1997·Physiological Reviews·G F DiBona, U C Kopp
Dec 21, 2000·Cardiovascular Research·R J Henning, D R Sawmiller
Feb 15, 2001·The New England Journal of Medicine·J RadermacherH Haller
Apr 1, 1958·Circulation·O M HELMER
Jun 2, 1962·Lancet·W I CRANSTON, B E JUEL-JENSEN
Dec 1, 1961·Diseases of the Chest·K NAKAYAMA
Oct 24, 2003·American Journal of Hypertension·Mari Konishi NishizakaDavid A Calhoun
Jan 7, 2004·Hypertension·Thomas E LohmeierRobert S Kieval
Jan 31, 2004·American Journal of Hypertension·Kazuo EguchiKazuyuki Shimada
May 12, 2004·Molecular and Cellular Endocrinology·Susan M Garthwaite, Ellen G McMahon
Nov 26, 2004·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Terry N Thrasher
Dec 18, 2004·Advances in Experimental Medicine and Biology·Benjamin Winter, Brian J Whipp
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Christophe Morisseau, Bruce D Hammock
Jan 25, 2006·Hypertension·Ernesto L Schiffrin
May 11, 2006·Journal of Hypertension·Joël MénardAlvine Bissery
Nov 1, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Wenxia Chai, A H Jan Danser
Nov 7, 2006·Journal of the American College of Cardiology·Bernard De BruyneGuy R Heyndrickx
Nov 30, 2006·Proceedings of the National Academy of Sciences of the United States of America·Danyan XuNipavan Chiamvimonvat
Dec 2, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Vera JankowskiJoachim Jankowski
Feb 21, 2007·Hypertension·Neil ChapmanUNKNOWN Anglo-Scandinavian Cardiac Outcomes Trial Investigators

❮ Previous
Next ❯

Citations

Dec 30, 2015·International Journal of Molecular Sciences·You-Lin Tain, Jaap A Joles
Feb 10, 2016·Frontiers in Physiology·Clênia de Oliveira CavalcantiCamille de Moura Balarini
Dec 15, 2015·Nature Reviews. Nephrology·Lilach O Lerman, Stephen C Textor
Dec 15, 2015·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Friedrich C Luft
Nov 19, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jordan DespanieJ Andrew MacKay
Jun 2, 2016·Experimental Physiology·Man-Lung Fung
Jun 25, 2016·JACC. Cardiovascular Interventions·Petr NeuzilRoland E Schmieder
Oct 27, 2015·The American Journal of Medicine·Michael A Bettmann
Oct 25, 2016·The Journal of Nutritional Biochemistry·Adrián Galiana-SimalBeatriz Martín-Fernández
Oct 28, 2016·Drugs·Alan C CameronRhian M Touyz
Oct 8, 2016·ACS Chemical Biology·Ken YamadaHyi-Man Park
Oct 26, 2016·Journal of Vascular Surgery·Sven Rupprecht
Feb 2, 2017·Journal of Clinical Pharmacology·Evan B WangGemma L Dickinson
Feb 7, 2017·Drug Delivery·Tausif AlamJaved Ali
Mar 14, 2017·Clinical and Experimental Hypertension : CHE·Anping CaiYingling Zhou
Jun 3, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Carlos M Ferrario, Adam E Mullick
May 26, 2017·Expert Opinion on Drug Discovery·Maria Tamargo, Juan Tamargo
Jun 9, 2016·Therapeutic Advances in Cardiovascular Disease·Rainer Düsing
Jun 24, 2017·Biosensors & Bioelectronics·Cristian SevcencuJohannes J Struijk
Mar 23, 2018·Nature Reviews. Disease Primers·Suzanne OparilPaul K Whelton
Oct 31, 2017·Current Opinion in Nephrology and Hypertension·Vikas KapilRoland E Schmieder
Apr 28, 2018·Current Opinion in Cardiology·Merrill H StewartHector O Ventura
Feb 25, 2018·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Mario Fritsch NevesWille Oigman
Jun 16, 2018·Clinical Science·Alynne Carvalho-GalvãoMaria do Socorro de França-Silva
Dec 25, 2017·Journal of the American Heart Association·Petr NeuzilUNKNOWN BackBeat Study Investigators
Mar 17, 2017·Circulation Research·Xue-Nan SunSheng-Zhong Duan
Mar 15, 2015·Circulation Research·Giuseppe Mancia
Jul 18, 2018·Journal of Hypertension·Roland E SchmiederUNKNOWN Members of the ESH Working Group on Interventional Treatment of Hypertension
Nov 17, 2016·Hypertension·George A MensahGary H Gibbons
Feb 12, 2017·F1000Research·Andrew J FreemanRobert E Widdop
Feb 15, 2018·Neuromodulation : Journal of the International Neuromodulation Society·Cristian SevcencuJohannes J Struijk
Mar 2, 2019·Clinical and Experimental Hypertension : CHE·Diogo Nóbrega CatelasPatricio Soares-Da-Silva
Mar 29, 2019·Circulation Research·Michel Burnier, Brent M Egan
Mar 9, 2019·Current Pharmaceutical Design·Konstantinos P ImprialosCharles Faselis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.